FMP
NASDAQ
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
2.48 USD
0.01 (0.403%)
Mr. Eric E. Easom
Healthcare
Biotechnology
https://www.an2therapeutics.com
NASDAQ
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
0001880438
US0373261058
037326105
1800 El Camino Real
650-331-9090
US
41
Mar 25, 2022